• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三十年来转移性乳腺癌患者生存趋势及预后因素的时变效应——单中心经验。

Thirty-Year Trends of Survival and Time-Varying Effects of Prognostic Factors in Patients With Metastatic Breast Cancer-A Single Institution Experience.

机构信息

Departement of Obstetrics and Gynaecology, Saint Vincent de Paul Hospital, Catholic University of Lille, Lille, France.

Departement of Obstetrics and Gynaecology, Saint Vincent de Paul Hospital, Catholic University of Lille, Lille, France.

出版信息

Clin Breast Cancer. 2018 Jun;18(3):246-253. doi: 10.1016/j.clbc.2017.08.012. Epub 2017 Sep 1.

DOI:10.1016/j.clbc.2017.08.012
PMID:28988656
Abstract

BACKGROUND

Metastatic breast cancer is generally considered an incurable disease. In our study we aimed to detect a time trend of survival over the past 30 years and account for time-varying effects of the prognostic factors.

PATIENTS AND METHODS

A total of 446 patients diagnosed with breast cancer at Saint Vincent de Paul Hospital, Lille, France between 1977 and 2013 who developed metastatic disease after a disease-free interval longer than 3 months and were followed-up for outcome. Data were analyzed using the Cox proportional hazards model and presented as hazard ratios (HRs).

RESULTS

A monotonic time trend of survival was detected: a 2.6% lower risk of death for each increasing year over the past 30 years. Three prognostic factors had time-varying effects; the liver first metastasis (HR during the first 16 months of follow-up: 2.26; 95% confidence interval [CI], 1.65-3.11), the bone first metastasis (HR during the first 24 months of follow-up: 0.56; 95% CI, 0.43-0.74), and the disease-free interval (HR during the first 16 months of follow-up: 0.90; 95% CI, 0.85-0.95). The brain first metastasis, multiple first metastases, the lymph node ratio, and estrogen receptor status had a constant effect over time.

CONCLUSION

In our study we detected a constant time trend of improvement in prognosis of metastatic breast cancer patients over the past 30 years and identified prognostic factors with time-varying effects.

摘要

背景

转移性乳腺癌一般被认为是一种不可治愈的疾病。在我们的研究中,我们旨在检测过去 30 年来生存时间的趋势,并考虑预后因素的时变效应。

患者和方法

共有 446 名在法国里尔圣文森特德保罗医院诊断为乳腺癌的患者,在无病间期超过 3 个月后发生转移性疾病,并进行了结局随访。使用 Cox 比例风险模型分析数据,并以风险比(HR)表示。

结果

检测到生存时间呈单调时间趋势:过去 30 年来,每年的死亡风险降低 2.6%。有三个预后因素具有时变效应;肝转移首发(随访前 16 个月的 HR:2.26;95%置信区间[CI],1.65-3.11)、骨转移首发(随访前 24 个月的 HR:0.56;95%CI,0.43-0.74)和无病间期(随访前 16 个月的 HR:0.90;95%CI,0.85-0.95)。脑转移首发、多发转移、淋巴结比率和雌激素受体状态的效应随时间保持不变。

结论

在我们的研究中,我们检测到过去 30 年来转移性乳腺癌患者预后持续改善的恒定时间趋势,并确定了具有时变效应的预后因素。

相似文献

1
Thirty-Year Trends of Survival and Time-Varying Effects of Prognostic Factors in Patients With Metastatic Breast Cancer-A Single Institution Experience.三十年来转移性乳腺癌患者生存趋势及预后因素的时变效应——单中心经验。
Clin Breast Cancer. 2018 Jun;18(3):246-253. doi: 10.1016/j.clbc.2017.08.012. Epub 2017 Sep 1.
2
Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience.乳腺癌患者无转移间期:三十年趋势和预后因素的时间依赖性。基于单机构经验的回顾性分析。
Breast. 2018 Feb;37:80-88. doi: 10.1016/j.breast.2017.10.008. Epub 2017 Nov 2.
3
De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.乳腺癌中的新发转移:按分子亚型分层的发生和总生存情况。
Clin Exp Metastasis. 2017 Dec;34(8):457-465. doi: 10.1007/s10585-017-9871-9. Epub 2017 Dec 29.
4
New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.激素受体阳性、HER2 阴性乳腺癌患者首发转移部位对生存影响的新认识:271 例患者的多中心研究。
BMC Cancer. 2021 Apr 29;21(1):476. doi: 10.1186/s12885-021-08219-3.
5
Prognostic factors in 401 elderly women with metastatic breast cancer.401 例老年女性转移性乳腺癌的预后因素。
Oncology. 2014;86(3):143-51. doi: 10.1159/000357781. Epub 2014 Feb 26.
6
Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.新发 IV 期三阴性乳腺癌中特定部位转移和手术的预后价值:基于人群的分析。
Med Sci Monit. 2020 Feb 11;26:e920432. doi: 10.12659/MSM.920432.
7
Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.转移性乳腺癌患者锁骨上转移灶的特征及转归:原发灶与转移灶受体状态的不一致性
Anticancer Res. 2018 Oct;38(10):6023-6026. doi: 10.21873/anticanres.12952.
8
Survival in patients with breast cancer with bone metastasis: a Danish population-based cohort study on the prognostic impact of initial stage of disease at breast cancer diagnosis and length of the bone metastasis-free interval.乳腺癌骨转移患者的生存情况:一项基于丹麦人群的队列研究,探讨乳腺癌诊断时疾病初始阶段及无骨转移间期长度的预后影响。
BMJ Open. 2015 Apr 29;5(4):e007702. doi: 10.1136/bmjopen-2015-007702.
9
Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.初诊时出现乳腺癌脑转移的女性患者,根据肿瘤亚型的预后因素和生存情况
Eur J Cancer. 2017 Mar;74:17-25. doi: 10.1016/j.ejca.2016.12.015. Epub 2017 Feb 6.
10
[Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].腹股沟淋巴结转移乳腺癌患者的临床病理特征及预后因素:附17例报告
Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):207-11. doi: 10.3760/cma.j.issn.0253-3766.2013.03.010.

引用本文的文献

1
A novel approach to the analysis of Overall Survival (OS) as response with Progression-Free Interval (PFI) as condition based on the RNA-seq expression data in The Cancer Genome Atlas (TCGA).基于癌症基因组图谱(TCGA)中 RNA 测序表达数据,采用一种新方法分析总生存期(OS)作为反应,以无进展间隔(PFI)作为条件。
BMC Bioinformatics. 2024 Sep 13;25(1):300. doi: 10.1186/s12859-024-05897-1.
2
Transcriptomic analysis revealed potential regulatory biomarkers and repurposable drugs for breast cancer treatment.转录组分析揭示了潜在的乳腺癌治疗调控生物标志物和可再利用药物。
Cancer Rep (Hoboken). 2024 May;7(5):e2009. doi: 10.1002/cnr2.2009.
3
Robust Identification of Differential Gene Expression Patterns from Multiple Transcriptomics Datasets for Early Diagnosis, Prognosis, and Therapies for Breast Cancer.
从多个转录组学数据集稳健识别差异基因表达模式,用于乳腺癌的早期诊断、预后和治疗。
Medicina (Kaunas). 2023 Sep 24;59(10):1705. doi: 10.3390/medicina59101705.
4
Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain.东北西班牙诊断出的乳腺癌患者死于癌症和心血管疾病的十年概率。
Int J Environ Res Public Health. 2022 Dec 27;20(1):405. doi: 10.3390/ijerph20010405.
5
Budget impact analysis of breast cancer medications: a systematic review.乳腺癌药物的预算影响分析:一项系统综述
J Pharm Policy Pract. 2022 Dec 29;15(1):105. doi: 10.1186/s40545-022-00493-1.
6
Development and validation of a short-term breast health measure as a supplement to screening mammography.一种短期乳房健康测量方法的开发与验证,作为乳腺钼靶筛查的补充手段
Biomark Res. 2022 Oct 25;10(1):76. doi: 10.1186/s40364-022-00420-1.
7
Nomogram Predicts the Role of Primary Tumor Surgery on Stage-IV Breast Cancer Patients: A SEER-Based Competing Risk Analysis Model.列线图预测原发性肿瘤手术在IV期乳腺癌患者中的作用:基于监测、流行病学和最终结果(SEER)的竞争风险分析模型
Front Oncol. 2022 May 4;12:819531. doi: 10.3389/fonc.2022.819531. eCollection 2022.
8
Metastatic Pattern Discriminates Survival Benefit of Type of Surgery in Patients With Stage IV Breast Cancer Based on SEER Database.基于监测、流行病学和最终结果(SEER)数据库,转移模式可区分IV期乳腺癌患者手术类型的生存获益。
Front Surg. 2021 Nov 3;8:696628. doi: 10.3389/fsurg.2021.696628. eCollection 2021.
9
Development and application of a dynamic prediction model for esophageal cancer.食管癌动态预测模型的开发与应用
Ann Transl Med. 2021 Oct;9(20):1546. doi: 10.21037/atm-21-4964.
10
Identification of Hub Genes to Regulate Breast Cancer Spinal Metastases by Bioinformatics Analyses.基于生物信息学分析鉴定调控乳腺癌脊柱转移的枢纽基因。
Comput Math Methods Med. 2021 May 12;2021:5548918. doi: 10.1155/2021/5548918. eCollection 2021.